spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  GELNIQUE 

 HSMN NewsFeed - 18 Nov 2014
Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2014
Antares Pharma Announces Promotion of Robert F. Apple to Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jan 2014
Antares Pharma Announces Availability of OTREXUP (Methotrexate) Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis (pJIA) in Children
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 19 Nov 2013
Antares Pharma Appoints David H. Bergstrom Ph.D. as Senior Vice President Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Nov 2012
Antares Pharma Announces Positive Results from Final MTX Medi-Jet(TM) Clinical Study
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 2 Jul 2012
Antares Pharma Appoints Jonathan S. Jaffe MD Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Dec 2011
Antares' Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
 HSMN NewsFeed - 16 Dec 2010
Watson and Richter Announce Exclusive License Agreement for Esmya
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Aug 2010
Watson Plans Q4 2010 ella(R) (ulipristal acetate) Emergency Contraceptive Launch
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Mar 2010
Watson Announces Agreement to Acquire U.S. Rights to Columbia Laboratories' CRINONE(R) Progesterone Gel Product Line
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 1 Feb 2010
Watson and HRA Pharma Announce Exclusive Licensing Agreement to Commercialize Novel Emergency Contraceptive in the U.S.
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Dec 2009
New Published Data Demonstrate Long-Term Safety, Efficacy and Tolerability of Watson's RAPAFLO(R) (silodosin) for Benign Prostatic Hyperplasia (BPH) Symptom Relief
Biopharmaceuticals Urology
 HSMN NewsFeed - 21 May 2009
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Biopharmaceuticals Urology
 HSMN NewsFeed - 8 May 2009
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Apr 2009
Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
Biopharmaceuticals Urology
 HSMN NewsFeed - 27 Jan 2009
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Biopharmaceuticals Drug Delivery Urology FDA
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.